Context: Radiotherapy is the cornerstone of treatment in nasopharyngeal cancer (NPC); the addition of chemotherapy has shown improved results.
Aims: To compare the results of concurrent chemoradiation with that of radiotherapy alone in NPC.
Materials And Methods: One hundred and ninety consecutive NPC patients, without distant metastasis, who reported to the institute from January 1992 to December 2001, received external-beam radiation to 66 Gy in 33 fractions. Seventy-five of these patients received concurrent chemotherapy with cisplatin and 5-fluorouracil (5-FU) for four cycles. We compared the results of treatment in these two groups.
Results: The 5-year disease-free survival rates were 40% and 60%, respectively, for patients who had radiotherapy alone and those who had chemoradiation (P = 0.002), while the median survival was 45 months and 60 months, respectively (P = 0.0028).
Conclusion: A significant improvement in local control and survival was observed by the addition of concurrent chemotherapy with cisplatin and 5-FU to radical radiation in this nonrandomized study on patients with NPC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4103/0973-1482.52798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TdT combined with Cas14a for the electrochemical biosensing of NPC-derived exosomes.
Bioelectrochemistry
January 2025
Shenzhen Baoan Authentic TCM Therapy Hospital, Shenzhen, 518101, China. Electronic address:
In this work, the electrochemical biosensor based on the subtle combination of terminal deoxynucleotidyl transferase (TdT), CRISPR/Cas14a, and magnetic nanoparticles (MNPs) was developed for the detection of nasopharyngeal carcinoma (NPC)-derived exosomes. Due to the synergistic effect of the following factors: the powerful elongation capacity of TdT for single-stranded DNA (ssDNA) with 3-hydroxy terminus, the outstanding trans-cleavage ability of CRISPR/Cas14a specifcally activated by the crRNA binding to target DNA, and the excellent separation ability of MNPs, the developed electrochemical biosensor exhibited high sensitivity for the detection of NPC-derived exosome, with a linear range from 6.0 × 10 ∼ 1.
View Article and Find Full Text PDFEfficacy and safety of PD-1 inhibitor plus chemotherapy in advanced nasopharyngeal carcinoma: A meta-analysis.
Tumori
January 2025
Department of Otolaryngology, Shaoxing People's Hospital, Shaoxing, China.
Background: The combination of programmed cell death protein 1 (PD-1) inhibitors and chemotherapy has shown promising results in the treatment of various malignancies. This meta-analysis aims to evaluate the effectiveness and safety of combing PD-1 inhibitor with chemotherapy in patients with advanced NPC.
Methods: A thorough search of the literature was carried out using comprehensive methods.
Prediction of Persistent Tumor Status in Nasopharyngeal Carcinoma Post-Radiotherapy-Related Treatment: A Machine Learning Approach.
Cancers (Basel)
December 2024
Artificial Intelligence Center, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
The duration of the response to radiotherapy-related treatment is a critical prognostic indicator for patients with nasopharyngeal carcinoma (NPC). Persistent tumor status, including residual tumor presence and early recurrence, is associated with poorer survival outcomes. To address this, we developed a prediction model to identify patients at a high risk of persistent tumor status prior to initiating treatment.
View Article and Find Full Text PDFRisk assessment and quality management in AIO based on CT-linac for nasopharyngeal carcinoma: An improved FMEA and FTA approach.
Med Phys
January 2025
State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, P. R. China.
Article Synopsis
- AIO radiotherapy integrates all conventional steps into one device, improving efficiency and reducing errors for cancer patients while facing challenges like software complexity and AI reliance.
- A risk assessment using FMEA and FTA was conducted to evaluate the quality management measures for nasopharyngeal carcinoma treatment.
- Results showed 86 failure modes identified, with risk priority numbers indicating varying levels of risk, emphasizing the importance of implementing quality management measures for safety.
A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies.
Eur J Cancer
November 2024
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Purpose: MAK683, a first-in-class and highly selective allosteric inhibitor of the embryonic ectoderm development subunit of polycomb repressive complex 2, has shown sustained antitumor activity in tumor xenograft models. This first-in-human phase 1/2 study evaluated the safety, pharmacokinetics (PK), and clinical activity of single-agent MAK683 in advanced malignancies.
Methods: MAK683 was administered fasted once daily or twice daily continuously in 28-day treatment cycles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!